Metformin and Risk of Cardiovascular Disease

Publisher： Karger

E-ISSN： 1421-9751|91|3|203-204

ISSN： 0008-6312

Source： Cardiology, Vol.91, Iss.3, 1999-09, pp. : 203-204

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cardiovascular disease risk of homeless patients

By Maxwell Janet Lie Jason

British Journal of General Practice, Vol. 58, Iss. 554, 2008-09 ,pp. : 648-649

Royal College of General Practitioners

Access to resources Recommend Favorite

Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study

By Goldstein Barry J. Weissman Peter N. Wooddell Margaret J. Waterhouse Brian R. Cobitz Alexander R.

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1715-1723

Informa Healthcare

Access to resources Recommend Favorite

The potential for CETP inhibition to reduce cardiovascular disease risk

By Ansell Benjamin Hobbs F. D. Richard

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2467-2478

Informa Healthcare

Access to resources Recommend Favorite

Providing food to treat adolescents at risk for cardiovascular disease

OBESITY, Vol. 1930-7381, Iss. 10, 2015-10 ,pp. : 2109-2117

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular disease in primary care: concordance and risk reduction

By Knapton Mike

British Journal of General Practice, Vol. 62, Iss. 599, 2012-06 ,pp. : 284-285

Royal College of General Practitioners

Access to resources Recommend Favorite